Bafna Pharmaceuticals Ltd
Ticker: BAFNAPH
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
149.84
Market Cap
354.47
Debt/Equity
0.3325
ROE %
5.011
PB
4.1795
Promoter %
75.000
Pledge %
0.000
1Y Rev Growth %
-4.737
5Y Rev Growth %
28.309
NP Margin %
2.793
NP Margin 5Y Avg %
6.234
Trading Reference
1M Return %
24.349
6M Return %
100.134
1Y Return %
83.853
% Away 52W High
17.679
% Away 52W Low
117.159
Daily Volume
1180
Investment Verdict
Hold
Score 63/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Watch
Score 65/100 · Position size: 10%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Bafna Pharmaceuticals Ltd is currently trading near a strong support level, with the 50-day EMA indicating a bullish trend. If the stock breaks above the resistance level, there is potential for significant upside. However, if it falls below the support, downside risks increase.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
N
NTC Industries Ltd
NTC Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
P
Power and Instrumentation (Gujarat) Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
G
G. G. Automotive Gears Ltd
G. G. Automotive Gears Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Star Paper Mills Ltd
Star Paper Mills Ltd presents several risks with limited growth prospects and weak market sentiment, making it a risky investment.
View details
T
T T Ltd
T T Ltd presents a mixed investment case with significant risks outweighing potential rewards. Caution is advised.
View details
C
CASHurDRIVE Marketing Ltd
CASHurDRIVE Marketing Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised for investors.
View details
M
M K Proteins Ltd
M K Proteins Ltd has a decent outlook with growth potential, but faces challenges in profitability and market sentiment.
View details
N
Nidhi Granites Ltd
Nidhi Granites Ltd shows potential but faces challenges in profitability and market sentiment. Caution is advised.
View details
C
Comfort Intech Ltd
Comfort Intech Ltd shows potential but faces challenges in growth and profitability metrics. Caution is advised.
View details
A
Aeroflex Neu Ltd
Aeroflex Neu Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Alacrity Securities Ltd
Alacrity Securities Ltd shows potential in a growing sector but faces challenges in growth consistency and market sentiment.
View details
R
Revathi Equipment India ltd
Revathi Equipment India Ltd shows potential in a growing sector, but faces challenges in consistency and valuation.
View details
N
Nephro Care India Ltd
Nephro Care India Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
B
Brahmaputra Infrastructure Ltd
Brahmaputra Infrastructure Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
J
Jeyyam Global Foods Ltd
Jeyyam Global Foods Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
G
Gennex Laboratories Ltd
Gennex Laboratories Ltd shows potential but faces significant risks and inconsistencies in growth and profitability.
View details
Business Overview
Bafna Pharmaceuticals Ltd is a leading player in the Indian pharmaceutical sector, specializing in the development and manufacturing of high-quality generic medicines. Catering to a diverse clientele, including hospitals and pharmacies, Bafna is committed to enhancing healthcare accessibility across the nation. With a focus on innovation and compliance with global standards, the company plays a crucial role in the pharmaceutical supply chain. Its strong distribution network and strategic partnerships position it for sustained growth in a competitive market.
- Established leader in generic pharmaceuticals
- Wide range of high-quality medicines
- Strong commitment to innovation
- Robust distribution network
- Focus on compliance with global standards
- Contributes to affordable healthcare in India
Investment Thesis
Bafna Pharmaceuticals Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. The company's robust fundamentals and strategic positioning make it a promising addition to any portfolio.
- Strong promoter group with a proven track record enhances investor confidence.
- Digital services segment poised for substantial growth, tapping into evolving market trends.
- Attractive valuation metrics compared to industry peers, offering potential for upside.
- Commitment to innovation and quality positions Bafna favorably in the pharmaceutical sector.
- Solid financial performance and growth trajectory support long-term investment rationale.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into new markets
- Strong product pipeline
- Potential for strategic partnerships
- Increasing online sales channels
Risks ⚠️
- Regulatory challenges in pharmaceuticals
- Intense competition in the sector
- Dependence on key suppliers
- Market volatility affecting sales
- Potential for product recalls
Peer Perspective
Bafna Pharmaceuticals Ltd trades at a discount compared to peers like Sun Pharma and Lupin, primarily due to margin volatility. A sustained improvement in margins could trigger a rerating, aligning its valuation more closely with industry leaders.
Future Outlook
Bafna Pharmaceuticals Ltd is well-positioned for growth, driven by expanding product lines and market reach. Successful execution of its strategic initiatives and effective cost control will be crucial for maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Bafna Pharmaceuticals Ltd do?A: Bafna Pharmaceuticals Ltd is involved in manufacturing and marketing pharmaceutical products, including generics and specialty medications.
- Q: Is Bafna Pharmaceuticals Ltd a good investment?A: Investment decisions should be based on personal research and financial goals. Consult a financial advisor for tailored advice.
- Q: What are the risks of investing in Bafna Pharmaceuticals Ltd?A: Risks include market volatility, regulatory changes, and competition within the pharmaceutical industry.
- Q: How can I buy shares of Bafna Pharmaceuticals Ltd?A: Shares can be purchased through a stockbroker or an online trading platform that offers access to Indian stock markets.
- Q: Where can I find financial information about Bafna Pharmaceuticals Ltd?A: Financial information is available on the company's official website, stock exchanges, and financial news platforms.
📊 Stock Investment Checklist (100 Points)
Bafna Pharmaceuticals Ltd • Updated: 2025-09-16 19:47:16
-
8BusinessHighPharmaceutical sector is growing with increasing healthcare demands.
-
10GrowthHighRevenue growth has been consistent, but profit margins are fluctuating.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is not consistently higher than net profit.
-
9ValuationHighP/E and P/B ratios are in line with industry averages.
-
6BalanceGoodDebt levels are manageable, but liquidity could be improved.
-
7GovernanceHighPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are notable.
-
1TechnicalsLowMarket sentiment is weak with low liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
Bafna Pharmaceuticals has a decent outlook with growth potential, but faces challenges in profitability and market sentiment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100